vs
安进（AMGN）与Krystal Biotech, Inc.（KRYS）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Krystal Biotech, Inc.的92.1倍（$9.9B vs $107.1M）。Krystal Biotech, Inc.净利率更高（48.0% vs 13.5%，领先34.5%）。Krystal Biotech, Inc.同比增速更快（17.5% vs 8.6%）。安进自由现金流更多（$961.0M vs $75.4M）。过去两年Krystal Biotech, Inc.的营收复合增速更高（53.8% vs 15.1%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Krystal Biotech是一家处于临床阶段的生物技术企业，专注于研发和商业化针对罕见重症皮肤病的新型基因疗法，主要面向北美和欧洲市场，服务缺乏有效常规治疗方案的单基因皮肤病患者。
AMGN vs KRYS — 直观对比
营收规模更大
AMGN
是对方的92.1倍
$107.1M
营收增速更快
KRYS
高出8.9%
8.6%
净利率更高
KRYS
高出34.5%
13.5%
自由现金流更多
AMGN
多$885.6M
$75.4M
两年增速更快
KRYS
近两年复合增速
15.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $107.1M |
| 净利润 | $1.3B | $51.4M |
| 毛利率 | 69.8% | — |
| 营业利润率 | 27.6% | 41.5% |
| 净利率 | 13.5% | 48.0% |
| 营收同比 | 8.6% | 17.5% |
| 净利润同比 | 112.6% | 13.0% |
| 每股收益（稀释后） | $2.45 | $1.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNKRYS
| Q4 25 | $9.9B | $107.1M | ||
| Q3 25 | $9.6B | $97.8M | ||
| Q2 25 | $9.2B | $96.0M | ||
| Q1 25 | $8.1B | $88.2M | ||
| Q4 24 | $9.1B | $91.1M | ||
| Q3 24 | $8.5B | $83.8M | ||
| Q2 24 | $8.4B | $70.3M | ||
| Q1 24 | $7.4B | $45.3M |
净利润AMGNKRYS
| Q4 25 | $1.3B | $51.4M | ||
| Q3 25 | $3.2B | $79.4M | ||
| Q2 25 | $1.4B | $38.3M | ||
| Q1 25 | $1.7B | $35.7M | ||
| Q4 24 | $627.0M | $45.5M | ||
| Q3 24 | $2.8B | $27.2M | ||
| Q2 24 | $746.0M | $15.6M | ||
| Q1 24 | $-113.0M | $932.0K |
毛利率AMGNKRYS
| Q4 25 | 69.8% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 63.6% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.4% | — | ||
| Q1 24 | 57.0% | — |
营业利润率AMGNKRYS
| Q4 25 | 27.6% | 41.5% | ||
| Q3 25 | 26.4% | 42.3% | ||
| Q2 25 | 28.9% | 40.9% | ||
| Q1 25 | 14.5% | 41.0% | ||
| Q4 24 | 25.4% | 45.4% | ||
| Q3 24 | 24.1% | 26.8% | ||
| Q2 24 | 22.8% | 12.2% | ||
| Q1 24 | 13.3% | -14.8% |
净利率AMGNKRYS
| Q4 25 | 13.5% | 48.0% | ||
| Q3 25 | 33.7% | 81.2% | ||
| Q2 25 | 15.6% | 39.9% | ||
| Q1 25 | 21.2% | 40.5% | ||
| Q4 24 | 6.9% | 49.9% | ||
| Q3 24 | 33.3% | 32.4% | ||
| Q2 24 | 8.9% | 22.2% | ||
| Q1 24 | -1.5% | 2.1% |
每股收益（稀释后）AMGNKRYS
| Q4 25 | $2.45 | $1.69 | ||
| Q3 25 | $5.93 | $2.66 | ||
| Q2 25 | $2.65 | $1.29 | ||
| Q1 25 | $3.20 | $1.20 | ||
| Q4 24 | $1.17 | $1.53 | ||
| Q3 24 | $5.22 | $0.91 | ||
| Q2 24 | $1.38 | $0.53 | ||
| Q1 24 | $-0.21 | $0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $496.3M |
| 总债务越低越好 | $54.6B | — |
| 股东权益账面价值 | $8.7B | $1.2B |
| 总资产 | $90.6B | $1.3B |
| 负债/权益比越低杠杆越低 | 6.31× | — |
8季度趋势，按日历期对齐
现金及短期投资AMGNKRYS
| Q4 25 | $9.1B | $496.3M | ||
| Q3 25 | $9.4B | $392.6M | ||
| Q2 25 | $8.0B | $353.8M | ||
| Q1 25 | $8.8B | $308.8M | ||
| Q4 24 | $12.0B | $344.9M | ||
| Q3 24 | $9.0B | $374.0M | ||
| Q2 24 | $9.3B | $345.8M | ||
| Q1 24 | $9.7B | $359.0M |
总债务AMGNKRYS
| Q4 25 | $54.6B | — | ||
| Q3 25 | $54.6B | — | ||
| Q2 25 | $56.2B | — | ||
| Q1 25 | $57.4B | — | ||
| Q4 24 | $60.1B | — | ||
| Q3 24 | $60.4B | — | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNKRYS
| Q4 25 | $8.7B | $1.2B | ||
| Q3 25 | $9.6B | $1.1B | ||
| Q2 25 | $7.4B | $1.0B | ||
| Q1 25 | $6.2B | $984.7M | ||
| Q4 24 | $5.9B | $946.4M | ||
| Q3 24 | $7.5B | $885.8M | ||
| Q2 24 | $5.9B | $838.9M | ||
| Q1 24 | $5.0B | $799.2M |
总资产AMGNKRYS
| Q4 25 | $90.6B | $1.3B | ||
| Q3 25 | $90.1B | $1.2B | ||
| Q2 25 | $87.9B | $1.1B | ||
| Q1 25 | $89.4B | $1.1B | ||
| Q4 24 | $91.8B | $1.1B | ||
| Q3 24 | $90.9B | $982.3M | ||
| Q2 24 | $90.9B | $917.7M | ||
| Q1 24 | $93.0B | $853.3M |
负债/权益比AMGNKRYS
| Q4 25 | 6.31× | — | ||
| Q3 25 | 5.67× | — | ||
| Q2 25 | 7.57× | — | ||
| Q1 25 | 9.24× | — | ||
| Q4 24 | 10.23× | — | ||
| Q3 24 | 8.02× | — | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $77.5M |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $75.4M |
| 自由现金流率自由现金流/营收 | 9.7% | 70.4% |
| 资本支出强度资本支出/营收 | 6.5% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.20× | 1.51× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $188.9M |
8季度趋势，按日历期对齐
经营现金流AMGNKRYS
| Q4 25 | $1.6B | $77.5M | ||
| Q3 25 | $4.7B | $39.7M | ||
| Q2 25 | $2.3B | $52.7M | ||
| Q1 25 | $1.4B | $31.0M | ||
| Q4 24 | $4.8B | $52.8M | ||
| Q3 24 | $3.6B | $58.9M | ||
| Q2 24 | $2.5B | $-4.2M | ||
| Q1 24 | $689.0M | $15.9M |
自由现金流AMGNKRYS
| Q4 25 | $961.0M | $75.4M | ||
| Q3 25 | $4.2B | $38.0M | ||
| Q2 25 | $1.9B | $50.8M | ||
| Q1 25 | $980.0M | $24.8M | ||
| Q4 24 | $4.4B | $52.0M | ||
| Q3 24 | $3.3B | $57.8M | ||
| Q2 24 | $2.2B | $-5.3M | ||
| Q1 24 | $459.0M | $14.6M |
自由现金流率AMGNKRYS
| Q4 25 | 9.7% | 70.4% | ||
| Q3 25 | 44.4% | 38.8% | ||
| Q2 25 | 20.8% | 52.9% | ||
| Q1 25 | 12.0% | 28.1% | ||
| Q4 24 | 48.4% | 57.1% | ||
| Q3 24 | 39.0% | 69.0% | ||
| Q2 24 | 26.5% | -7.5% | ||
| Q1 24 | 6.2% | 32.3% |
资本支出强度AMGNKRYS
| Q4 25 | 6.5% | 2.0% | ||
| Q3 25 | 4.6% | 1.7% | ||
| Q2 25 | 4.0% | 2.0% | ||
| Q1 25 | 5.0% | 7.0% | ||
| Q4 24 | 4.1% | 0.9% | ||
| Q3 24 | 3.0% | 1.2% | ||
| Q2 24 | 2.8% | 1.6% | ||
| Q1 24 | 3.1% | 2.8% |
现金转化率AMGNKRYS
| Q4 25 | 1.20× | 1.51× | ||
| Q3 25 | 1.46× | 0.50× | ||
| Q2 25 | 1.59× | 1.38× | ||
| Q1 25 | 0.80× | 0.87× | ||
| Q4 24 | 7.61× | 1.16× | ||
| Q3 24 | 1.26× | 2.17× | ||
| Q2 24 | 3.30× | -0.27× | ||
| Q1 24 | — | 17.05× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
KRYS
暂无分部数据
